DAPASUG-TG 20
MRP: 1,600
Packaging: 10x10
Pack Type: tablet
Composition:
Dapagliflozin 10mg + Teneligliptin 20mg
Indication:
Ensure Victory in controlling Diabetes
Description:
Dapagliflozin 10mg + Teneligliptin 20mg is an advanced oral antidiabetic combination therapy used for managing type 2 diabetes mellitus. This fixed-dose combination leverages two distinct mechanisms to achieve better glycemic control:
Dapagliflozin is an SGLT2 inhibitor that reduces blood glucose by enhancing urinary glucose excretion.
Teneligliptin is a DPP-4 inhibitor that increases incretin levels, thereby stimulating insulin secretion and decreasing glucagon production.
This dual-action combination not only helps in reducing fasting and postprandial blood glucose levels but also supports weight loss and has a low risk of hypoglycemia. It is prescribed as part of a comprehensive diabetes management plan including diet and exercise.
Tags:
- Dual mechanism for superior blood glucose control
- Helps reduce HbA1c, fasting and postprandial glucose
- Promotes weight loss and lowers blood pressure (via Dapagliflozin)
- Enhances insulin secretion and reduces glucagon levels
- Convenient once-daily oral dose
- Low risk of hypoglycemia as monotherapy
Usage Information
Dosage
Typical Dose: One tablet once daily or as directed by the physician Route: Oral Timing: Can be taken with or without meals Note: Follow the exact dose prescribed by your healthcare provider. Do not skip or double doses.
Side Effects
Urinary tract infections Increased urination Genital fungal infections Headache Constipation Nasopharyngitis Hypoglycemia (when combined with other medications) Dizziness or dehydration (especially in elderly patients) Seek medical attention if you experience allergic reactions, symptoms of ketoacidosis, or signs of urinary tract infections.
Contraindications
Type 1 diabetes mellitus Diabetic ketoacidosis Moderate to severe renal impairment Hypersensitivity to Dapagliflozin, Teneligliptin, or excipients Severe liver disease (use with caution) History of recurrent urinary tract infections